U.S. Markets closed

FDA approves Zohydro ER for management of severe pain

he U.S. Food and Drug Administration approved Zohydro ER for the management of pain severe enough to require daily, around-the-clock, long-term treatment and for which alternative treatment options are inadequate. Zohydro ER, a Schedule II controlled substance under the Controlled Substances Act, is the first FDA-approved single-entity and extended-release hydrocodone product. The approved labeling for Zohydro ER conforms to updated labeling requirements for all ER/LA opioid analgesics announced by the FDA on Sept. 10 and Zohydro ER will be part of the ER/LA Opioid Analgesics Risk Evaluation and Mitigation Strategy. Zohydro ER is manufactured by Zogenix.